Literature DB >> 6979554

Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

J Alcocer-Varela, D Alarcón-Segovia.   

Abstract

We studied the production of and response to interleukin-2 (IL-2) by peripheral blood T lymphocytes from 19 systemic lupus erythematosus (SLE) patients who received no treatment at the time they were studied. Eight had active disease and the rest were in remission. Results were compared with those obtained in 12 healthy subjects of similar age. T cells from SLE patients, whether activated with phytohemagglutinin or in autologous mixed lymphocyte reactions, were found to yield little IL-2, to have a low response to IL-2 from its own, or other sources, and to absorb IL-2 poorly, IL-2 produced by SLE cells, albeit scant, was absorbed normally by activated T cells from normal subjects. Our findings may contribute to the understanding of the immunoregulatory defect in SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979554      PMCID: PMC370212          DOI: 10.1172/jci110579

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Molecular and quantitative analysis of helper T cell-replacing factors on the induction of antigen-sensitive B and T lymphocytes.

Authors:  J Watson; L A Aarden; J Shaw; V Paetkau
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

2.  The cellular basis of the impaired autologous mixed lymphocyte reaction in patients with systemic lupus erythematosus.

Authors:  M M Kuntz; J B Innes; M E Weksler
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

Review 3.  Glucocorticoids and immune responses.

Authors:  G R Crabtree; S Gillis; K A Smith; A Munck
Journal:  Arthritis Rheum       Date:  1979-11

4.  Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into Tgamma lymphocytes causing their deletion and the abrogation of suppressor function.

Authors:  D Alarcon-Segovia; A Ruiz-Arguelles; L Llorente
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Continued growth of functional human T lymphocytes: production of human T-cell growth factor.

Authors:  G D Bonnard; K Yasaka; R D Maca
Journal:  Cell Immunol       Date:  1980-05       Impact factor: 4.868

7.  Suppressor-cell antibody in systemic lupus erythematosus. Possible mechanism for suppressor-cell dysfunction.

Authors:  A Sagawa; N I Abdou
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

8.  Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; A Ruíz-Argüelles
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

9.  Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function.

Authors:  J F Delfraissy; P Segond; P Galanaud; C Wallon; P Massias; J Dormont
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

10.  Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies.

Authors:  D A Horwitz; M A Garrett; A H Craig
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

View more
  128 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Interleukin-2 production in Brown-Norway rats with HgCl2-induced autoimmune disease: paradoxical in vivo versus in vitro findings.

Authors:  D Baran; O Lantz; P Dosquet; A Sfaksi; P Druet
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

4.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

5.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

6.  Interleukin 2 receptor bearing T lymphocytes in patients with chronic liver disease.

Authors:  S Kakumu; K Yoshioka; A Fuji; H Tahara
Journal:  Gastroenterol Jpn       Date:  1988-08

Review 7.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

8.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 10.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.